Correction: Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review
Pharmacopsychiatry · 01.05.2024 · 57 (03) · e2
DOI: 10.1055/a-2775-0902 ↗Kurz gefasst
Korrektur in der Zeitschrift Pharmacopsychiatry, erschienen am 01.05.2024. Verfasst von Inga Dammann und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dept. of Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Dept. of Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany.
- R&D, Endosane Pharmaceuticals GmbH, Berlin, Germany.
- Brain and Mind Centre, Translational Research Collective, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
ORCID-Profile: F Markus Leweke
Zitieren
APA
Dammann, I., Rohleder, C., & Leweke, F. M. (2024). Correction: Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review. Pharmacopsychiatry, 57(03), e2. https://doi.org/10.1055/a-2775-0902
Vancouver
Dammann I, Rohleder C, Leweke FM. Correction: Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review. Pharmacopsychiatry. 2024;57(03):e2. doi:10.1055/a-2775-0902
BibTeX
@article{Dammann2024,
author = {Dammann, Inga and Rohleder, Cathrin and Leweke, F Markus},
title = {Correction: Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review},
journal = {Pharmacopsychiatry},
year = {2024},
volume = {57},
number = {03},
pages = {e2},
doi = {10.1055/a-2775-0902}
}
EUVIMED